Last updated: June 25, 2026

Executive summary: Solifenacin succinate, an oral antimuscarinic for overactive bladder (OAB), has moved through the typical post-patent lifecycle into a generally generic-heavy U.S. and ex-U.S. landscape. Market dynamics are driven by (1) pricing pressure from multiple ANDA entrants, (2) channel-level switching to preferred formulary agents across OAB classes, and (3) persistent differentiation only at the formulation/brand-contract layer. Financial trajectory is best characterized as steady-to-declining branded revenue after patent expiry, with total category growth offset by share loss and net price erosion. The risk profile is medium: multiple regulatory pathways can accelerate generic erosion once exclusivities and last bottleneck patents expire, but solifenacin’s entrenched guideline positioning reduces demand volatility.

What is the current market size and demand profile for solifenacin succinate in overactive bladder (OAB)?

Solifenacin succinate is a widely used oral antimuscarinic for OAB symptom control (commonly urinary urgency, frequency, and urge incontinence). The demand profile is driven by prevalence of OAB, treatment adherence for chronic symptom management, and payer formulary design that increasingly limits step therapy and targets cost-effective agents.

Key demand characteristics

Chronic, symptom-driven use: Patients stay on therapy as long as tolerability remains acceptable (dry mouth, constipation, blurred vision are common).
Switching within OAB class: When net pricing becomes less competitive for any single product, pharmacy benefit managers typically steer to lower-cost antimuscarinics or to β3-agonists (e.g., mirabegron, vibegron) depending on formulary strategy.
Dose and adherence matter: Once-daily oral dosing supports adherence relative to some older multi-dose regimens, but adherence still declines when side effects accumulate over time.

Which geographies show the most pricing pressure for solifenacin succinate?

Featured pressure points typically align with regions that have:

High generic penetration (U.S., parts of EU/UK where national pricing and tendering occur)
Tender-driven reimbursement structures
Mature OAB formularies with multiple equivalent antimuscarinic options

How fast has solifenacin lost branded share versus generic?

Branded share loss is expected after key patent and marketing exclusivity end. In practice, branded revenues tend to decline as:

Generic pricing collapses vs brand acquisition cost
Payor formularies update to prefer generics or lower-cost therapeutic alternatives
Pharmacy-level dispensing shifts as rebates and contract terms change

What competitive dynamics shape solifenacin succinate pricing and market share?

Competitive dynamics are defined less by clinical superiority and more by economic placement. Solifenacin’s competitive set spans:

Other antimuscarinics (immediate- and extended-release)
β3-adrenergic agonists (often used as alternatives when antimuscarinics do not meet tolerability)

How do antimuscarinic-to-β3 switching patterns affect revenues?

If payers or clinicians shift OAB patients from antimuscarinics to β3-agonists based on tolerability and patient preference, solifenacin’s addressable market can narrow. The magnitude depends on:

Regional guideline emphasis
Formulary preference tiers
Rebate economics and net cost per treated patient

What contract and tender mechanisms influence net pricing?

Net price depends on:

Pharmacy benefit manager preferred drug lists (PDLs)
Hospital and clinic tendering (where solifenacin competes on unit price)
Co-pay card or patient assistance availability for branded products (where still active)

What are the main substitution risks for solifenacin succinate?

Therapeutic substitution: β3 agonists reduce anticholinergic side-effect burden for some patients.
Within-class substitution: Multiple antimuscarinics provide prescribers and payers with interchangeable options.
Formulary restrictions: Prior authorization and step edits can steer toward preferred lower-cost agents.

What is the financial trajectory of solifenacin succinate: revenue trends, profitability, and unit economics?

Base case trajectory: Branded revenue typically declines after exclusivity, while generic volumes can rise. Company-level profit depends on whether a firm holds manufacturing scale, distribution reach, and favorable procurement terms.

What drives generic revenue and margin stability after launch?

Generic margins are pressured by:

Price erosion among multiple ANDA competitors
Contract-driven rebate costs
Manufacturing cost variability (API, solubility controls, consistent dissolution profiles for extended-release)

What unit economics determine long-run survivability of generic solifenacin products?

Formulation complexity: If the extended-release or specific delivery characteristics raise manufacturing burden, margins can be somewhat more stable than “simple oral” products.
Market share dispersion: Multiple entrants can push prices down quickly; fewer entrants support pricing durability.
Customer concentration: If supply agreements tie manufacturers to a small number of distributors/wholesalers, volume loss or contract renegotiation can hit revenue sharply.

What financial tail risks can accelerate erosion?

New entrants that win significant contract placements
Litigation-driven market entry changes (settlements or exclusivity challenges)
Changes in FDA labeling, if they broaden or narrow eligibility

When does solifenacin succinate face exclusivity and patent expiration-driven generic entry risk?

Market entry timing is the core “calendar risk” for pharmaceutical revenue. For solifenacin succinate, the practical question is not “does generic exist,” but “when do late bottlenecks clear and what exclusivity still delays entry in particular strengths or dosage forms.”

What exclusivity types matter for solifenacin succinate?

For small molecules, exclusivity bottlenecks usually include:

Patents covering formulation, method of use, and manufacturing controls
Potential regulatory exclusivities tied to NDA changes (less common once the drug is mature)
Orange Book-listed patents that can block ANDA approval until expiration or settlement

How do Paragraph IV challenges affect solifenacin pricing?

Paragraph IV litigation can:

Trigger earlier-than-expected generic launches after settlements
Shift bargaining power among generic companies
Create temporary price rebounds for brand products if stays or injunctions delay entry

What is the Orange Book status of solifenacin succinate products in the U.S.?

Orange Book listings dictate which patents can block ANDA approval. The operational impact:

If multiple patents still list and are not expired, ANDA launch can be delayed or require carve-outs
If only weak or soon-expiring patents remain, generic entry tends to accelerate

Market consequence: Once the Orange Book bottlenecks clear, solifenacin succinate tends to transition to multi-competitor generic pricing equilibrium.

Which companies manufacture and market solifenacin succinate in the U.S. and major export markets?

Typical market structure for mature solifenacin:

Branded product owners (where still present) plus
Multi-generic manufacturers selling strengths and dosage forms via distributors
Contract manufacturing that can reduce supply risk for distributors but increases price competition

Commercial implication: The most meaningful differentiators among generics are usually:

Ability to supply consistently
Compliance records
Contract positioning with wholesalers and PBMs

What patent estate issues determine how strong IP is for solifenacin succinate?

At this lifecycle stage, IP strength is usually expressed as:

Whether any late-expiring patents still cover specific dosage forms, controlled release mechanisms, or process parameters
Whether method-of-use or formulation patents narrow easy “design-around” options

Which IP categories typically create late bottlenecks for oral OAB drugs?

Controlled-release matrix patents
Specific dissolution profile targets and manufacturing process controls
Crystalline form and solid-state property claims (when applicable)
Secondary patents tied to dosing regimens (method-of-use)

How does solifenacin succinate compare with mirabegron and vibegron in market economics?

Solifenacin competes with β3 agonists that often gain formulary placement where tolerability is a priority. Price competition is not purely direct; it is payer-driven.

What economic comparison matters for payers?

Net cost per patient over time including adherence and discontinuation rates
Prior authorization complexity
Patient out-of-pocket exposure under tiered copay structures

How does efficacy perception affect formularies?

For mature OAB therapies, formulary placement tends to follow:

Real-world tolerability
Net price and rebate structure
Administrative simplicity

What generic entry scenarios could change solifenacin succinate revenue outlook?

For solifenacin, generic entry scenarios typically revolve around:

Strength/dosage-specific bottleneck clearance
Settlement timing after Paragraph IV challenges
Launch of “authorized generics” (less common at this stage but relevant if it occurs)

Scenario framework

Fast-clear scenario: Multiple bottlenecks expire in close succession; pricing drops quickly and share redistributes to lowest net-cost sellers.
Staggered-clear scenario: Only one or two patents expire per year; competition increases gradually, with smaller net price declines.
Litigation-delay scenario: A late injunction or settlement shifts launch timing; brand product gains temporary revenue retention.

What FDA and regulatory factors influence solifenacin succinate continuity and supply?

Regulatory factors affecting near- and mid-term supply include:

ANDA approval schedules
Inspection outcomes for manufacturing sites
Labeling changes that affect interchangeability

How can regulatory events affect pricing?

A site compliance issue can reduce supply for a supplier, briefly supporting pricing.
A labeling update can shift substitution decisions in pharmacy workflows.

What is the litigation landscape risk for solifenacin succinate?

For mature drugs, most litigation risk manifests as:

Paragraph IV challenges targeting Orange Book patents
Settlement agreements that define “exit timing” for certain patent claims
Follow-on litigation over additional bottlenecks

Commercial implication: Litigation tends to be a timing catalyst for step-function revenue changes around generic entry windows.

How do settlement agreements and licensing deals typically impact solifenacin revenue?

When settlements occur, they usually:

Set an agreed launch date for specific generic products
Define allowable patent carve-outs or design-around boundaries
Influence which generic competitors launch first and at what strength

Financial impact: Early settlement generally compresses brand revenue by pulling forward generic erosion. Delayed settlement can extend brand net revenue if the brand retains favorable contracts.

What dosage forms and formulations drive product-level variation in revenue?

Solifenacin succinate is typically sold as an oral tablet (extended-release). Revenue can vary by:

Strength mix (10 mg vs 5 mg)
Formulation equivalence and dissolution profile consistency
Contract preferences for specific strengths

What formulation patents matter most for oral extended-release OAB products?

Manufacturing and release-characteristic patents often govern how easily manufacturers can replicate the drug without infringing.

Key Takeaways

Solifenacin succinate’s financial trajectory is primarily driven by generic penetration and payer formulary economics, not by clinical differentiation.
Branded revenues have followed a post-exclusivity decline pattern, with generic volume gains partially offsetting price erosion.
Competitive forces include both within-class antimuscarinic switching and therapeutic substitution to β3 agonists.
The largest near- to mid-term revenue inflection points occur when Orange Book bottlenecks clear or when Paragraph IV litigation accelerates entry through settlements.
Sustained supply and contract positioning determine which manufacturers capture lasting share once multi-competitor pricing equilibrium sets in.

FAQs

How do Orange Book patent expirations for solifenacin succinate translate into ANDA launch timing?
Which OAB drug class substitution trends most affect solifenacin succinate share: antimuscarinics or β3 agonists?
Do solifenacin generics face formulation bottlenecks in extended-release dissolution or manufacturing process validation?
What settlement and litigation patterns typically determine the first wave of solifenacin generic entrants?
How do PBM formulary tiering and rebates determine net pricing erosion for solifenacin succinate products?

References (APA)

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-06-25).

International Patents:	23
US Patents:	1
Tradenames:	3
Applicants:	27
NDAs:	28
Drug Master File Entries:	29
Finished Product Suppliers / Packagers:	21
Raw Ingredient (Bulk) Api Vendors:	71
Clinical Trials:	59
Patent Applications:	3,644
Drug Prices:	Drug price trends for SOLIFENACIN SUCCINATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SOLIFENACIN SUCCINATE
What excipients (inactive ingredients) are in SOLIFENACIN SUCCINATE?	SOLIFENACIN SUCCINATE excipients list
DailyMed Link:	SOLIFENACIN SUCCINATE at DailyMed

Sponsor	Phase
Xing Liu	NA
Shanghai University of Traditional Chinese Medicine	N/A
Longhua Hospital	N/A

Drug Class	Cholinergic Muscarinic Antagonist
Mechanism of Action	Cholinergic Muscarinic Antagonists

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VESICARE LS	Oral Suspension	solifenacin succinate	1 mg/mL	209529	1	2021-05-27
VESICARE	Tablets	solifenacin succinate	5 mg and 10 mg	021518	1	2009-04-08

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Annora Pharma	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	215761-001	Jun 15, 2022	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Aurobindo Pharma	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	206817-002	Dec 27, 2022	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sunshine	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	213346-002	Apr 13, 2020	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Qilu	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	209333-001	May 20, 2019	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Country	Patent Number	Title	Estimated Expiration
Australia	2011255951	Pharmaceutical composition containing solifenacin	⤷ Start Trial
Brazil	112012029461	composição farmacêutica contendo solifenacina	⤷ Start Trial
Canada	2799942	COMPOSITION PHARMACEUTIQUE CONTENANT DE LA SOLIFENACINE (PHARMACEUTICAL COMPOSITION CONTAINING SOLIFENACIN)	⤷ Start Trial
China	102905706	Pharmaceutical composition containing solifenacin	⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0801067	04C0032	France	⤷ Start Trial	PRODUCT NAME: SUCCINATE DE SOLIFENACINE; NAT. REGISTRATION NO/DATE: NL 30 109 20040816; FIRST REGISTRATION: NL - RVG 29 151 20031216
0801067	C00801067/01	Switzerland	⤷ Start Trial	PRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006
0801067	SPC/GB04/029	United Kingdom	⤷ Start Trial	PRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Summary for SOLIFENACIN SUCCINATE

Recent Clinical Trials for SOLIFENACIN SUCCINATE

Pharmacology for SOLIFENACIN SUCCINATE

Medical Subject Heading (MeSH) Categories for SOLIFENACIN SUCCINATE

Anatomical Therapeutic Chemical (ATC) Classes for SOLIFENACIN SUCCINATE

Paragraph IV (Patent) Challenges for SOLIFENACIN SUCCINATE